Saturday 17 October 2026 Export GRFS’s income statement to Excel — free account

Grifols, S.A.

GRFS Healthcare Drug Manufacturers General

Grifols, S.A.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 billion, up 9.07% from fiscal 2024. In the quarter to June 2026, revenue grew 5.76%, EPS grew 466.9%, free cash flow grew 300.5% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.

7.64 0.10 +1.33%

Follow GRFS

Alert me

Market cap: $2.0B
P/E: 8.5×
Fwd P/E: —
Dividend yield: 1.24%
F-score: 5/9
Altman Z: 1.38
Beneish M: −2.59
Dividend safety: 54/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 62.08%

Capital & Financial Ratios $m

Market Cap 1,950.00

Revenue 8,620.98

Net Income 766.11

Free Cash Flow 739.71

Net Debt 10,049.21

Current Ratio 2.37

Debt/Equity 1.17

P/E ratio 8.46

Fwd P/E —

P/S ratio 0.60

P/B ratio 0.56

Past 5Y EPS Growth (8.24%)

This Y EPS Growth 12.43%

Next Y EPS Growth 29.32%

Next Y revenue growth —

Next 5Y EPS Growth 24.35%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 2.47%

10-year low 10-year high

P/S against its own 10 years 13.14%

10-year low 10-year high

P/B against its own 10 years 13.54%

10-year low 10-year high

EV/Sales against its own 10 years 16.88%

10-year low 10-year high

EV/FCF against its own 10 years 1.80%

10-year low 10-year high

Dividends

Payout Ratio 0.10

Annual Dividend Rate 0.09

Annual Dividend Yield 1.24%

	total	individual payouts
2026	0.09	0.09
2025	0.18	0.18
2021	0.46	0.46
2020	0.20	0.20
2019	0.40	0.18 0.22
2018	0.23	0.25 0.23
2017	0.38	0.16 0.21
2016	0.36	0.16 0.19

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	725	1,324	974	829
Receivables	779	847	851	999
Inventory	3,744	3,852	3,729	4,060
Other	183	174	187	278
	6,983	6,198	5,741	6,168

	2023	2024	2025	Q'26
Payables	880	922	952	1,164
ST’ Debt	1,108	732	625	637
Other	358	386	395	380
	2,506	2,333	2,284	2,600

Compound Annual Growth %

	10y	5y	3y
Sales	6.90%	6.89%	10.04%
Cash Flow	3.69%	(1.36%)	0.00%
Earnings	(2.58%)	(8.43%)	27.50%
Book Value	8.90%	2.30%	(1.17%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	1,990	—	—	—	—
’25	1,881	2,147	2,180	2,304	8,513
’24	—	1,958	1,972	—	7,805
’23	1,676	1,814	1,620	—	7,134
’22	—	1,642	—	3,462	6,389
’21	1,428	1,629	—	2,723	5,836
’20	1,417	1,555	1,592	1,616	6,100

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	129	263	—	—	—
’25	143	187	390	464	1,185
’24	—	95	331	—	976
’23	(66)	(47)	278	—	225
’22	—	34	—	(38)	(11)
’21	214	409	—	303	706
’20	115	491	364	332	1,268

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	23	129	—	—	—
’25	50	32	259	328	711
’24	—	(53)	228	—	600
’23	(134)	(113)	241	—	(88)
’22	—	(115)	—	(38)	(404)
’22	—	—	—	—	0
’21	142	249	—	303	627

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	0.19	—	0.60	0.67
’24	—	0.02	—	—	0.25
’23	—	0.09	—	—	0.10
’22	—	0.14	—	0.11	0.33
’21	0.23	0.24	—	(0.14)	0.32
’20	0.30	0.06	0.46	0.23	1.03

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	14.07	15.90	17.42	17.57	13.40	10.10	5.71	6.50	5.30	6.19	Analyst estimates 2026–2028 Powerpack
	High	17.40	24.20	25.18	23.65	25.73	20.49	13.34	12.15	11.73	11.14
People
People	Employees	14,877	18,296	21,230	22,244	23,668	23,234	26,314	23,737	23,822	25,247
	Revenue/emp, $m	0.30	0.27	0.25	0.26	0.26	0.25	0.24	0.30	0.33	0.34
Income, $m
Income, $m	Revenue	4,482	4,881	5,299	5,711	6,100	5,836	6,389	7,134	7,805	8,513
	Gross margin, %	47.22	49.84	45.68	45.92	42.23	39.78	36.80	37.84	38.75	38.00
	EBT	789	786	857	915	1,004	415	381	242	480	696
	EBT margin, %	17.60	16.11	16.18	16.03	16.45	7.10	5.96	3.40	6.16	8.17
	Net income	789	786	857	915	1,004	415	381	242	480	696
	Depreciation	223	244	270	339	367	426	430	478	474	509
Per share, $
Per share, $	Revenue	6.56	7.13	7.74	8.34	8.90	8.56	9.40	10.50	11.48	12.51
	Earnings	0.89	1.10	1.03	1.02	1.03	0.32	0.33	0.10	0.25	0.67
	Cash flow	0.90	1.39	1.27	0.93	1.85	1.04	(0.02)	0.33	1.44	1.74
	Capex	(0.47)	(0.53)	(0.53)	(0.67)	(0.60)	(0.12)	(0.58)	(0.46)	(0.55)	(0.70)
	Free cash flow	0.43	0.86	0.74	0.26	1.25	0.92	(0.59)	(0.13)	0.88	1.04
	Book value	6.04	6.00	8.10	11.19	11.20	12.70	13.11	12.69	13.70	12.64
	Shares, m	683	684	685	685	686	682	680	680	680	681
Valuation, ×
Valuation, ×	P/E	17.89	26.00	18.73	20.33	17.64	19.76	24.97	55.25	20.88	10.35
	P/S	2.45	3.43	2.55	2.92	2.04	0.39	0.24	0.00	0.75	0.75
	P/B	2.67	4.07	2.62	2.97	2.00	0.42	0.34	0.00	0.94	0.74
	EV/Sales	3.45	4.70	3.90	3.87	3.31	1.72	1.27	1.34	2.10	1.91
	EV/FCF	53.17	44.08	38.49	52.13	33.44	25.33	1,462.80	(59.21)	51.23	25.24
Cash, $m
Cash, $m	Operating cash flow	612	951	871	637	1,268	706	(11)	225	976	1,185
	Capex	(321)	(364)	(363)	(459)	(414)	(79)	(392)	(314)	(376)	(474)
	Free cash flow	291	587	508	178	854	627	(404)	(88)	600	711
Balance, $m
Balance, $m	Working capital	2,269	2,224	2,629	4,475	2,090	2,409	2,842	4,477	3,865	3,456
	Total debt	5,469	6,846	7,539	8,074	8,027	12,076	11,333	11,967	11,001	10,910
	Net debt	4,476	5,832	6,255	5,306	7,352	8,899	10,709	11,242	9,678	9,936
	Shareholders’ equity	4,125	4,107	5,547	7,667	7,676	8,657	8,911	8,629	9,314	8,602
Returns, %
Returns, %	ROA	5.52	6.36	5.20	4.36	4.05	1.11	0.97	0.28	0.73	2.00
	ROIC	7.55	7.13	6.22	6.10	4.73	2.51	2.70	2.72	4.24	4.74
	ROE	15.49	18.20	14.60	10.60	9.21	2.73	2.50	0.73	1.89	5.08

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NVO Novo Nordisk A/S	$131.2B	9.5×	—	+4.47% (above 0%: growing)	−18.68% (below 0%: shrinking)	+71.57% (above 0%: growing)	78.21%	34.48%	Compare
BMY Bristol Myers Squibb Company	$123.7B	13.2×	11.2×	+5.74% (above 0%: growing)	+153.13% (above 0%: growing)	−13.16% (below 0%: shrinking)	71.28%	31.50%	Compare
GSK GSK PLC Sponsored ADR	$98.2B	15.4×	12.4×	+5.81% (above 0%: growing)	−69.47% (below 0%: shrinking)	+54.83% (above 0%: growing)	73.05%	5.72%	Compare
SNY Sanofi	$96.0B	21.3×	—	+17.35% (above 0%: growing)	−90.76% (below 0%: shrinking)	−45.06% (below 0%: shrinking)	75.47%	17.48%	Compare
BIIB Biogen Inc.	$34.8B	41.0×	31.5×	+3.42% (above 0%: growing)	−84.76% (below 0%: shrinking)	+103.28% (above 0%: growing)	71.60%	5.52%	Compare
OGN Organon & Co.	$3.6B	17.4×	5.2×	−2.26% (below 0%: shrinking)	−26.79% (below 0%: shrinking)	−82.97% (below 0%: shrinking)	54.36%	20.67%	Compare
GRFS Grifols, S.A.	$2.0B	8.5×	—	+5.76% (above 0%: growing)	+466.92% (above 0%: growing)	+300.52% (above 0%: growing)	36.47%	14.76%
AMRN Amarin Corporation PLC	$244.4M	— (loss-making)	— (loss-making)	−41.97% (below 0%: shrinking)	n/m	−60.23% (below 0%: shrinking)	35.51%	(28.45%)	Compare
NSRX Nasus Pharma Ltd.	$37.1M	—	—	—	—	−486.98% (below 0%: shrinking)	—	—	Compare
Median of peers	$65.4B	16.4×	11.8×	+4.47%	−48.13%	−29.11%	71.60%	17.48%

All 21 Drug Manufacturers General stocks →

Grifols, S.A. (GRFS) key facts

Strength: Grifols, S.A.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 billion, up 9.07% from fiscal 2024.
Grifols, S.A. (GRFS) is a Drug Manufacturers General company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, GRFS traded at $7.64, a market capitalization of $2.0 billion.
Grifols, S.A. pays an annual dividend of $0.09 per share, a yield of 1.24%, with a payout ratio of 10.5%.
Return on equity was 5.08% and debt-to-equity 1.17.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 1.38 (distress zone) for fiscal 2025.